Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on December 22, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 39,625 shares of common stock to 4 new employees.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Each stock option has an exercise price per share equal to $12.24 the fair market value on December 30, 2011, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Each stock option was effective as of December 30, 2011, and also has a ten year term and is subject to the terms and conditions of the Company's 2006 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Optimer in accordance with NASDAQ Listing Rule 5635(c)(4).

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

 

 

 

 


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
2. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
3. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
4. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
5. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
8. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
10. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , January 23, 2017 Stock-Callers.com ... Pharmaceuticals Inc. (NASDAQ: CPRX ), Sophiris Bio Inc. ... MNTA ), and Agile Therapeutics Inc. (NASDAQ: ... which turned somewhat lower in late trade on Friday, January ... dropping about 0.3%, while shares of health care companies in ...
(Date:1/23/2017)... , 23. Januar 2017  ResMed (NYSE: ... und 3B Medical ( Winter Haven, Florida ... Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten zwischen den ... Verkauf ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren ... an 3B leisten, um das in Florida ...
(Date:1/22/2017)... ABU DHABI , Saudi Arabia , January 22, 2017 ... the US and UAE ... Future , at the World Economic Forum   ... be driven by big data and powered by artificial intelligence and this trend ... that discussed the ,Hospital of the Future, at the concluding day of the ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company ... recently met with big-name retail buyers at the January ECRM Trade Show in Hilton ... uses the utmost safety standards in all of its creations to help create a ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a company that ... product to the United States as part of its presence to expand its market ... aims to reduce the productions of nasty toxins as a result of drinking alcohol, ...
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global business ... recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly ... to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
Breaking Medicine News(10 mins):